Switch theme
Sign up to access all valuation multiples
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
2020
1.2K+
LTM Revenue $5.4B
LTM EBITDA $1.4B
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vimian Group has a last 12-month revenue (LTM) of $5.4B and a last 12-month EBITDA of $1.4B.
In the most recent fiscal year, Vimian Group achieved revenue of $39.2M and an EBITDA of $9.2M.
Vimian Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vimian Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.4B | XXX | $39.2M | XXX | XXX | XXX |
| Gross Profit | $3.8B | XXX | $27.0M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $1.4B | XXX | $9.2M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $992M | XXX | $5.2M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $390M | XXX | $1.9M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $15.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Vimian Group's stock price is SEK 37 (or $4).
Vimian Group has current market cap of SEK 19.6B (or $2.1B), and EV of SEK 22.2B (or $2.3B).
See Vimian Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.1B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Vimian Group has market cap of $2.1B and EV of $2.3B.
Vimian Group's trades at 59.2x EV/Revenue multiple, and 252.0x EV/EBITDA.
Equity research analysts estimate Vimian Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vimian Group has a P/E ratio of 59.2x.
See valuation multiples for Vimian Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 59.2x | XXX | XXX | XXX |
| EV/EBITDA | 18.3x | XXX | 252.0x | XXX | XXX | XXX |
| EV/EBIT | 26.3x | XXX | 448.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.2x | XXX | 1060.1x | XXX | XXX | XXX |
| EV/FCF | 163.0x | XXX | 505.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVimian Group's last 12 month revenue growth is 11%
Vimian Group's revenue per employee in the last FY averaged $33K, while opex per employee averaged $18K for the same period.
Vimian Group's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vimian Group's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vimian Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 275% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 331% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $18K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vimian Group acquired XXX companies to date.
Last acquisition by Vimian Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Vimian Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vimian Group founded? | Vimian Group was founded in 2020. |
| Where is Vimian Group headquartered? | Vimian Group is headquartered in Sweden. |
| How many employees does Vimian Group have? | As of today, Vimian Group has 1.2K+ employees. |
| Who is the CEO of Vimian Group? | Vimian Group's CEO is Mr. Patrik Eriksson. |
| Is Vimian Group publicy listed? | Yes, Vimian Group is a public company listed on STO. |
| What is the stock symbol of Vimian Group? | Vimian Group trades under VIMIAN ticker. |
| When did Vimian Group go public? | Vimian Group went public in 2021. |
| Who are competitors of Vimian Group? | Similar companies to Vimian Group include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Vimian Group? | Vimian Group's current market cap is $2.1B |
| What is the current revenue of Vimian Group? | Vimian Group's last 12 months revenue is $5.4B. |
| What is the current revenue growth of Vimian Group? | Vimian Group revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Vimian Group? | Current revenue multiple of Vimian Group is 4.9x. |
| Is Vimian Group profitable? | Yes, Vimian Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vimian Group? | Vimian Group's last 12 months EBITDA is $1.4B. |
| What is Vimian Group's EBITDA margin? | Vimian Group's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Vimian Group? | Current EBITDA multiple of Vimian Group is 18.3x. |
| What is the current FCF of Vimian Group? | Vimian Group's last 12 months FCF is $160M. |
| What is Vimian Group's FCF margin? | Vimian Group's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Vimian Group? | Current FCF multiple of Vimian Group is 163.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
